|
Myocardial Infarction
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Thus, our results suggest that Rev-erb alpha is a major determinant of the circadian PAI-1 expression and a potential modulator of the morning susceptibility to myocardial infarction.
|
16968709 |
2006 |
|
Myocardial Infarction
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Elevated levels of plasminogen activator inhibitor-1 (PAI-1) are associated with myocardial infarction and stroke, especially in patients with diabetes.
|
15956119 |
2005 |
|
Myocardial Infarction
|
0.300 |
Biomarker
|
disease |
RGD |
Downregulated expression of plasminogen activator inhibitor-1 augments myocardial neovascularization and reduces cardiomyocyte apoptosis after acute myocardial infarction.
|
16053971 |
2005 |
|
Myocardial Infarction
|
0.300 |
Biomarker
|
disease |
LHGDN |
However, healthy persons and patients with previous myocardial infarction differed regarding coronary risk factors associated with PAI-1.
|
15678273 |
2005 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
LHGDN |
Recent large Japanese case-control studies identified connexin-37 (GJA-4), plasminogen activator inhibitor-1 (PAI-1), and stromelysin-1 (MMP-3) polymorphisms as risk factors for MI, but the prevalence of these genotypes among different racial groups in the U.S. needs to be determined.
|
15234427 |
2004 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Recent large Japanese case-control studies identified connexin-37 (GJA-4), plasminogen activator inhibitor-1 (PAI-1), and stromelysin-1 (MMP-3) polymorphisms as risk factors for MI, but the prevalence of these genotypes among different racial groups in the U.S. needs to be determined.
|
15234427 |
2004 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
To examine interactions among the angiotensin converting enzyme (ACE) insertion/deletion, plasminogen activator inhibitor-1 (PAI-1) 4G/5G, and tissue plasminogen activator (t-PA) insertion/deletion gene polymorphisms on risk of myocardial infarction using data from 343 matched case-control pairs from the Physicians Health Study.
|
15119966 |
2004 |
|
Myocardial Infarction
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
These results identify a causal relationship between elevated PAI-1 levels and poor outcome in patients with myocardial infarction through mechanisms that directly inhibit bone marrow-dependent neovascularization.
|
15596522 |
2004 |
|
Myocardial Infarction
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Plasminogen activator inhibitor-1 (PAI-1) activity post myocardial infarction: the role of acute phase reactants, insulin-like molecules and promoter (4G/5G) polymorphism in the PAI-1 gene.
|
12801613 |
2003 |
|
Myocardial Infarction
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The adjusted odds ratio (OR) of MI was 1.9 (95% confidence interval [CI] 1.4-2.8) for men with a plasma PAI-1 activity level greater than the 90 th percentile value of referents.
|
12783120 |
2003 |
|
Myocardial Infarction
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The 4G allele was associated with significantly higher PAI-1 levels in cases but not controls and, taken independently, did not modify the risk of MI (P=0.9).
|
14629464 |
2003 |
|
Myocardial Infarction
|
0.300 |
Biomarker
|
disease |
BEFREE |
MPO and PAI-1 are shown to have a critical role in the LV response immediately after MI, as demonstrated by markedly delayed myocardial rupture in the MPO(-/-) and accelerated rupture in the PAI-1(-/-).
|
12615902 |
2003 |
|
Myocardial Infarction
|
0.300 |
AlteredExpression
|
disease |
LHGDN |
Plasminogen activator inhibitor-1 (PAI-1) activity post myocardial infarction: the role of acute phase reactants, insulin-like molecules and promoter (4G/5G) polymorphism in the PAI-1 gene.
|
12801613 |
2003 |
|
Myocardial Infarction
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The plasma PAI-1 activity level in the MI group was lowered as the presence of the 4G allele decreases.
|
14642142 |
2003 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
We have prospectively evaluated the effect of plasminogen activator inhibitor-1 (PAI-1) 4G/5G and angiotensin-converting enzyme (ACE) insertion/deletion (I/D) polymorphisms on the occurrence of MI in uraemics.
|
12748347 |
2003 |
|
Myocardial Infarction
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The PAI-1 promoter 4G/5G polymorphism, furthermore, regulates free plasma PAI-1 levels in patients with myocardial infarction.
|
12065877 |
2002 |
|
Myocardial Infarction
|
0.300 |
Biomarker
|
disease |
LHGDN |
Plasminogen activator inhibitor in patients with acute myocardial infarction and re-infarction in syndrome X.
|
11934213 |
2002 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms of the angiotensin-converting enzyme (ACE) (insertion/deletion (I/D) in intron 16) and of the plasminogen activator inhibitor-1 (PAI-1) (promoter 4G/5G) genes have been linked with coronary heart disease (CHD) and/or myocardial infarction (MI).
|
11427204 |
2001 |
|
Myocardial Infarction
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
In summary our results suggest that the impairment of fibrinolytic activity resulting from elevated levels of PAI-1 antigen and activity and t-PA antigen is an independent variable in CDS associated with the premature occurrence of myocardial infarction in male patients with FH.
|
11253736 |
2001 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Homozygosity for the fibrinogen -455A allele was significantly associated with a decreased risk of myocardial infarction (OR 0.66, 95% CI 0.44 to 0.99, P=0.04), whereas the PAI-1 4G4G genotype was significantly associated with increased risk (OR 1.20, 95% CI 1.04 to 1.39, P=0.04).
|
11748101 |
2001 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
This study indicates that the 4G/5G gene polymorphism of PAI-1 is associated with myocardial infarction, that 4G/4G type is probably an important hereditary risk factor, and that glucose has functional importance in regulating PAI-1 activity.
|
11780311 |
2001 |
|
Myocardial Infarction
|
0.300 |
Biomarker
|
disease |
LHGDN |
We conclude that the imbalances of PAI-I/tPA and TF/TFPI are significantly associated with MI at a young age, perhaps mediated via impaired fibrinolytic activity.
|
11816707 |
2001 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The PAI-1 4G/5G genotype was not associated with risk of myocardial infarction or other cardiovascular mortality.
|
10618306 |
2000 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
05), total cholesterol (OR 1.35, 95% CI 1.11 to 1.65), plasminogen activator inhibitor-1 4G/4G (OR 1.72, 95% CI 1.20 to 2.45), and CRP levels >0.33 mg/L (OR 1.75, 95% CI 1.05 to 2.91) were all independently associated with a positive family history of myocardial infarction.
|
10634818 |
2000 |
|
Myocardial Infarction
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism, coronary thrombosis, and myocardial infarction in middle-aged Finnish men who died suddenly.
|
10928474 |
2000 |